]>
IRCT20151222025660N2 IRCT 2020-05-04 Arak University of Medical Sciences The prophylactic effect of Hydroxychloroquine on Novel Corona virus The prophylactic effect of Hydroxychloroquine on Novel Corona virus (COVID-19) in health care providers 2020-04-13 anticipated 90 Complete https://irct.ir/trial/47319 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Other, Purpose: Prevention, Randomization description: This study will conducted in two referral hospitals for COVID-19 in Arak. For logistical reasons, we will to randomly allocate the staff of one hospital in the intervention group and the other hospital in the control group. 3 COVID-19. Intervention 1: Intervention group: They will receive 400 mg of hydroxychloroquine (Tehran Darou, Iran) a week for eight weeks and also this group will receive routine care for Corona's new disease. Intervention 2: Control group: They will receive routine care for Corona's new disease. Yes - There is a plan to make this available What will be shared: All data is shared When: After completing the study To whom: Public Conditions: There are no other conditions Where to obtain: Phone number: 09127760893 How to obtain: 1 month after coordination with the executor whose number was mentioned above Comments:
public Dr.Ramin Parvizrad
Khorram Ave, valiasr hospital
Arak Iran (Islamic Republic of) 8962534125 +98 86 3222 0099 r.parvizrad@arakmu.ac.ir Arak University of Medical Sciences scientific Dr.Ramin Parvizrad
Khorram Ave, valiasr hospital
Arak Iran (Islamic Republic of) 8965236512 +98 86 3222 0099 r.parvizrad@arakmu.ac.ir Arak University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) consent to participate in the study People working in medical centers in Arak city Lack of sensitivity to hydroxychloroquine Lack of G6PD Lack of porphyria No breastfeeding No pregnancy Lack of diabetes, kidney , liver and skin disease no limit no limit Both Lack of desire to continue studying Having major side effects from medication U07.1 COVID-19, virus identified Prevention Other Intervention group: They will receive 400 mg of hydroxychloroquine (Tehran Darou, Iran) a week for eight weeks and also this group will receive routine care for Corona's new disease. Control group: They will receive routine care for Corona's new disease The number of confirmed cases. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist. Serum CRP levels and cellular immunity (cd8 / cd4 ratio) are assessed at the beginning and end of the study for all subjects. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist. The two groups will also be examined in terms of disease severity (need for intubation, ICU hospitalization) and absolute lymphocyte count. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist. Arak University of Medical Sciences Approved 2020-03-15 Ethics committee of Arak University of Medical Sciences A'lam-Al-Hoda Street, Shahid Shiroodi Street, Arak, Markazi Province, Iran arak Markazi Iran (Islamic Republic of)